In the phase I inMMyCAR study of the in vivo chimeric antigen receptor (CAR) T-cell therapy KLN-1010, all 18 patients with multiple myeloma responded. None of the evaluable patients had minimal residual disease 1 month after treatment, sugg...
For people with localized, high-risk prostate cancer, treatment with 6 months of apalutamide and androgen deprivation therapy (ADT) both before and after surgery reduces the risk of metastases and death compared with perioperative ADT alone...
A pan-cancer single-cell analysis of intratumoral copy number diversity and evolution [0.03%]
泛癌症单细胞分析肿瘤内拷贝数多样性及演化现象
Hanghui Ye,Thomas O McDonald,Reem Elghaish et al.
Hanghui Ye et al.
Aneuploidy is a hallmark of human tumors. While patient-level copy number alteration (CNA) differences have been investigated extensively in large cohorts, their intratumoral heterogeneity remains understudied. Here, we conducted a pan-canc...
The treatment arsenal for small cell lung cancer could soon include antibody-drug conjugates, with early data from three phase I studies indicating robust response rates to CD56-targeting DXC006, DLL-3-targeting BL-M14D1, and B7-H3-targetin...
Gut pathobionts translocate into liver and reshape intrahepatic microbiome to facilitate hepatocellular carcinoma [0.03%]
肠部病原共生菌易位至肝脏并重塑肝内微生物组以促进肝细胞癌的发展
Weixin Liu,Xueliang Wang,Ying Zhang et al.
Weixin Liu et al.
The role of intrahepatic microbiome in hepatocellular carcinoma (HCC) remains elusive. Here, we profiled matched gut and intrahepatic microbiomes from HCC patients and healthy subjects. Compared to healthy subjects, we observed increased gu...
Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers [0.03%]
多种组合疗法可对抗PD-(L)1耐药性并治疗罕见癌症
The ERAP1 inhibitor GRWD5769 combined with cemiplimab, a PD-1 inhibitor, has shown preliminary promise in overcoming resistance to PD-(L)1 blockade by targeting antigen processing. Another resistance-mitigating strategy is potentially IOS-1...
The anti-PD-1, anti-VEGF bispecific antibody ivonescimab plus chemotherapy significantly improves overall survival in advanced squamous non-small cell lung cancer versus an immunotherapy-chemotherapy combination, according to a trial conduc...